Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
TNFRSF17 as a complementary biomarker to PD-L1 for predicting the response to immunotherapy in urothelial bladder cancer
Saved in:
| Published in: | PLOS ONE |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: TNFRSF17 as a complementary biomarker to PD-L1 for predicting the response to immunotherapy in urothelial bladder cancer
- Emerging Predictive Biomarkers of Immunotherapy Sensitivity in Patients with Non-Small Cell Lung Cancer
- Multi-Omics Analysis Reveals m7G Methylation-Related Genes May Be Involved in TGF-β Signaling-Mediated Anti-PD-L1 Response in Bladder Cancer
- Overexpression of human epidermal growth factor receptor 2 protein in urothelial carcinoma of the urinary bladder in Ibadan: a single-institutional experience
- The Role of PD-L1 in Lung Cancer: From Biology to Clinical Application
- Endocrine advantages of PD-1/PD-L1 therapy: Comparative analysis of FAERS-JADER
- Correction: Endocrine advantages of PD-1/PD-L1 therapy: Comparative analysis of FAERS-JADER